Abd El-Karim Somaia S, Anwar Manal M, Syam Yasmin M, Awad Hassan M, El-Dein Asmaa Negm, El-Ashrey Mohamed K, Alkahtani Hamad M, Abdelwahed Sameh H
Department of Therapeutic Chemistry, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo 12622, Egypt.
Chemistry of Natural and Microbial Products Department, Pharmaceutical and Drug Industries Research Institute, National Research Centre, Dokki, Cairo 12622, Egypt.
Pharmaceuticals (Basel). 2024 Dec 10;17(12):1664. doi: 10.3390/ph17121664.
BACKGROUND/OBJECTIVES: The alarming rise in antibiotic resistance necessitates the discovery of novel antimicrobial agents. This study aims to design, synthesize, and evaluate new benzofuran-pyrazole-based compounds for their antimicrobial, antioxidant, and anti-inflammatory properties.
New benzofuran-pyrazole hybrid molecules were synthesized using the Vilsmeier-Haach reaction and other chemical processes. The structures of the synthesized compounds were confirmed through micro-analytical and spectral analyses. Their antimicrobial activities were assessed against various bacterial and fungal strains, while antioxidant and anti-inflammatory properties were evaluated using DPPH-free radical scavenging and HRBC membrane stabilization assays, respectively. The most promising compounds were further tested for DNA gyrase B inhibition.
Compounds , , and - exhibited significant broad-spectrum antimicrobial activity with MIC values ranging from 2.50 to 20 µg/mL. Compounds and demonstrated high antioxidant activity, with DPPH scavenging percentages between 84.16% and 90.52%. Most compounds showed substantial anti-inflammatory effects, with HRBC membrane stabilization percentages ranging from 86.70% to 99.25%. Compound notably inhibited E. coli DNA gyrase B with an IC50 of 9.80 µM, comparable to ciprofloxacin.
The benzofuran-pyrazole-based compounds, particularly compound , show great potential as new antimicrobial agents due to their broad-spectrum activity and potent DNA gyrase B inhibition. These findings support further development and optimization of these compounds for clinical applications.
背景/目的:抗生素耐药性的惊人上升使得发现新型抗菌剂成为必要。本研究旨在设计、合成并评估新型苯并呋喃 - 吡唑类化合物的抗菌、抗氧化和抗炎特性。
使用维尔斯迈尔 - 哈赫反应和其他化学过程合成新型苯并呋喃 - 吡唑杂化分子。通过微量分析和光谱分析确认合成化合物的结构。评估它们对各种细菌和真菌菌株的抗菌活性,同时分别使用DPPH自由基清除法和HRBC膜稳定试验评估抗氧化和抗炎特性。对最有前景的化合物进一步测试其对DNA促旋酶B的抑制作用。
化合物 、 和 - 表现出显著的广谱抗菌活性,MIC值范围为2.50至20μg/mL。化合物 和 表现出高抗氧化活性,DPPH清除率在84.16%至90.52%之间。大多数化合物显示出显著的抗炎作用,HRBC膜稳定率范围为86.70%至99.25%。化合物 尤其能抑制大肠杆菌DNA促旋酶B,IC50为9.80μM,与环丙沙星相当。
基于苯并呋喃 - 吡唑的化合物,特别是化合物 ,由于其广谱活性和对DNA促旋酶B的有效抑制,作为新型抗菌剂具有巨大潜力。这些发现支持进一步开发和优化这些化合物用于临床应用。